Parliamentary committee says redress scheme is not enough
Chinese probe into GSK’s prices has its parallel back home
Further government reviews of SMEs’ funding are not the answer
Big pharma companies are defending payments to producers of low-cost rivals, says Andrew Jack
OFT will wait for branch sales by Lloyds and RBS before considering competition
UK probe may be unwelcome but any financial damage should be absorbable
International Edition